drug
atogepant
Marketedupdated 3mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.
all catalysts(6)
approval · 6
Sep 28, 2021
approval
$ABBV261.83-1.56%
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Apr 17, 2023
approval
$ABBV261.83-1.56%
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Mar 21, 2025
approval
$ABBV261.83-1.56%
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Jun 10, 2025
approval
$ABBV261.83-1.56%
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Jun 10, 2025
approval
$ABBV261.83-1.56%
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Sep 30, 2025
approval
$ABBV261.83-1.56%
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Trials studying atogepant
- phase4Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- phase3A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- phase3A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- —Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
- phase3Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
- phase3Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
- phase3Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- phase3A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 28, 2026
38 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (20)
- Feb 27, 2043method-of-use (U-4234)US 12350259
- Sep 27, 2042method-of-use (U-4355)US 12465598
- Jul 29, 2041method-of-use (U-3534)US 12090148
- Jul 29, 2041method-of-use (U-3534)US 12090148
- Jul 29, 2041method-of-use (U-3534)US 12090148
- Jun 6, 2039method-of-use (U-3534)US 12383545
- Jun 6, 2039method-of-use (U-3534)US 12383545
- Jun 6, 2039method-of-use (U-3534)US 12383545
- Jan 30, 2035formulationUS 10117836
- Jan 30, 2035formulationUS 10117836
- Jan 30, 2035formulationUS 10117836
- Mar 13, 2033compositionUS 9850246
- Mar 13, 2033compositionUS 9850246
- Mar 13, 2033compositionUS 9850246
- Jul 19, 2032compositionUS 8754096
- Jul 19, 2032compositionUS 8754096
- Jul 19, 2032compositionUS 8754096
- Nov 10, 2031compositionUS 9499545
- Nov 10, 2031compositionUS 9499545
- Nov 10, 2031compositionUS 9499545
FDA exclusivities (6)
- Sep 28, 2026NCENew Chemical Entity (5y)38d
- Sep 28, 2026NCENew Chemical Entity (5y)38d
- Sep 28, 2026NCENew Chemical Entity (5y)38d
- Apr 17, 2026I-909Indication (3y)
- Apr 17, 2026I-909Indication (3y)
- Apr 17, 2026I-909Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that